Prescription medicine
Risankizumab Brand names: Skyrizi
Risankizumab (Skyrizi) is a prescription medicine. No generic is listed; pharmacies paid $22,774.36 per mL (Skyrizi 150 mg/mL pen) in the October 7, 2026 NADAC survey.
- No generic listed
Check it at the source: the risankizumab FDA label on DailyMed (effective June 15, 2026); every risankizumab label on DailyMed.
Highlights of the record
FDA label of June 15, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageSKYRIZI is an interleukin-23 antagonist indicated for the treatment of: moderate-to-severe plaque psoriasis in adults and pediatric patients 6 years of age and older who are candidates for systemic therapy or phototherapy.
Forms and strengths
- 55 mg/.37ml
- 150 mg/ml
- 180 mg/1.2ml
- 600 mg/10ml
Injection; kit; injection (solution).
On the market
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $22,774.36 per mL Skyrizi 150 mg/mL pen
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 81,290 through July 30, 2026
What is risankizumab used for?
From the label: indications and usageSKYRIZI is an interleukin-23 antagonist indicated for the treatment of: moderate-to-severe plaque psoriasis in adults and pediatric patients 6 years of age and older who are candidates for systemic therapy or phototherapy. ( 1.1 ) active psoriatic arthritis in adults and pediatric patients 6 years of age and older. ( 1.2 ) moderately to severely active Crohn's disease in adults. ( 1.3 ) moderately to severely active ulcerative colitis in adults. […]
Conditions named in the indications of risankizumab's FDA labels, with every medicine labeled for each:
From other risankizumab labelsPsoriasis: Plaque Psoriasis SKYRIZI ® is indicated for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 6 years of age and older who are candidates for systemic therapy or phototherapy.
Crohn's disease and ulcerative colitis: Crohn’s Disease SKYRIZI is indicated for the treatment of moderately to severely active Crohn's disease in adults.
FDA pharmacologic class: Interleukin-23 Antagonist.
Source: FDA drug label (Skyrizi), AbbVie Inc., effective June 15, 2026 (SPL set 7148c8eb-b39e-e20a-6494-a6df82392858), via openFDA; the full label on DailyMed
What does the patient leaflet for risankizumab say first?
The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.
From the patient leaflet: What is the most important information I should know about SKYRIZI?SKYRIZI may cause serious side effects, including: Serious allergic reactions. Stop using SKYRIZI and get emergency medical help right away if you get any of the following symptoms of a serious allergic reaction: ● fainting, dizziness, feeling lightheaded (low blood pressure) ● chest tightness ● swelling of your face, eyelids, lips, mouth, tongue, or throat ● skin rash, hives ● trouble breathing or throat tightness ● itching Infections. SKYRIZI may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with SKYRIZI and may treat you for TB before you begin treatment with SKYRIZI if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with SKYRIZI. Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including: ● fever, sweats, or chills ● muscle aches ● weight loss ● cough ● warm, red, or painful skin or sores on your body different from your psoriasis ● diarrhea or stomach pain ● shortness of breath ● burning when you urinate or urinating more often than normal ● blood in your mucus (phlegm) See “What are the possible side effects of SKYRIZI?” for more information about side effects.
From the patient leaflet: How should I store SKYRIZI?Store SKYRIZI in the refrigerator between 36°F to 46°F (2°C to 8°C). Do not freeze SKYRIZI. Do not shake SKYRIZI. Keep SKYRIZI in the original carton to protect it from light. SKYRIZI is not made with natural rubber latex. Keep SKYRIZI and all medicines out of the reach of children.
Source: FDA drug label (Skyrizi), AbbVie Inc., effective June 15, 2026 (SPL set 7148c8eb-b39e-e20a-6494-a6df82392858), via openFDA; the full label on DailyMed
Is there a generic for risankizumab (Skyrizi)?
No generic risankizumab is approved (Drugs@FDA, October 8, 2026).
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for risankizumab (Skyrizi)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $22,774.36 per mL (Skyrizi 150 mg/mL pen), up 6% from $21,439.45 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Skyrizi 360 mg/2.4 mL on-body (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Skyrizi 150 mg/mL pen | Brand | $22,774.36 per mL | n/a | +6% |
| Skyrizi 150 mg/mL syringe | Brand | $22,887.44 per mL | n/a | +6% |
| Skyrizi 360 mg/2.4 mL on-body | Brand | $9,572.67 per mL | n/a | +6% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What does the risankizumab label say about other medicines?
The risankizumab label names 1 other medicine in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Isoniazid | warnings and precautions | Two subjects taking isoniazid for treatment of latent TB discontinued treatment due to liver injury. |
Source: FDA drug label (Skyrizi), AbbVie Inc., effective June 15, 2026 (SPL set 7148c8eb-b39e-e20a-6494-a6df82392858), via openFDA; the full label on DailyMed
What do FAERS reports show for risankizumab?
The FDA Adverse Event Reporting System holds 81,290 reports that list risankizumab among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 2,905 are coded as a death and 18,119 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is. Reports rose sharply in 2025 (19,570, against a median of 1,931 a year): FAERS counts follow reporting, which news, litigation and label changes can drive, not how often a reaction happens.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as risankizumab?
11 other medicines are given the same way (subcutaneous) and in the same FDA class as risankizumab or labeled mainly for the same use (psoriasis), the same class first. Psoriasis lists all 38 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (subcutaneous) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Ustekinumab | Crohn's disease and ulcerative colitis | none listed | $29,874.45 per mL 45 mg/0.5 mL syringe | No current entry |
| Ustekinumab-aekn | Crohn's disease and ulcerative colitis | none listed | n/a | No current entry |
| Guselkumab | Crohn's disease and ulcerative colitis | none listed | $14,728.91 per mL 100 mg/mL syringe | No current entry |
| Ustekinumab-srlf | Crohn's disease and ulcerative colitis | none listed | n/a | No current entry |
| Tildrakizumab | Psoriasis | none listed | n/a | No current entry |
| Adalimumab-ryvk | Crohn's disease and ulcerative colitis, Psoriasis | none listed | $499.12 per unit 40 mg/0.4 mL autoinjector | A presentation being discontinued |
| Bimekizumab | Psoriasis | none listed | $8,073.83 per mL 160 mg/mL autoinjector | No current entry |
| Ixekizumab | Psoriasis | none listed | $7,370.72 per mL 80 mg/mL autoinjector | No current entry |
Every medicine labeled for the same conditions as risankizumab
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
How does risankizumab compare with medicines for the same use?
3 side-by-side pages set risankizumab beside a medicine whose label shares a use: approvals, generics, pharmacy cost, warnings and supply.
What next?
- Alternatives to risankizumab
- 11 medicines for the same use
- Other interleukin-23 antagonists
- the pharmacologic class, with prices and generics
- Risankizumab side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other